PAPER Lo I, Hill J, Vilhjálmsson BJ, Kjems J
SEARCH RESULTS
1477 RESULTS
PAPER Stummer L, Markovic M, Maroney M
Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease.
Neurodegener Dis Manag. 2020 Aug;10(4):205-217. Epub 2020 Jul 3 PubMed: 32618483PAPER Soares Martins T, Trindade D, Vaz M, Campelo I, Almeida M, Trigo G, da Cruz E Silva OA, Henriques AG
Diagnostic and therapeutic potential of exosomes in Alzheimer's disease.
J Neurochem. 2020 Jul 3; PubMed: 32618370PAPER Eravuchira P, Banchelli M, D'Andrea C, De Angelis M, Matteini P, Gannot I
Hollow core photonic crystal fiber-assisted Raman spectroscopy as a tool for the detection of Alzheimer's disease biomarkers.
J Biomed Opt. 2020 Jul;25(7):1-10. PubMed: 32618152PAPER Sun Y, Sommerville NR, Liu JY, Ngan MP, Poon D, Ponomarev ED, Lu Z, Kung JS, Rudd JA
Intra-gastrointestinal amyloid-β1-42 oligomers perturb enteric function and induce Alzheimer's disease pathology.
J Physiol. 2020 Oct;598(19):4209-4223. Epub 2020 Jul 6 PubMed: 32617993PAPER Orimaye SO, Southerland JL, Oke AO, Ajibade A
Increased Prevalence in Alzheimer Disease in the Northeast Tennessee Region of the United States.
South Med J. 2020 Jul;113(7):351-355. PubMed: 32617597PAPER Volloch V, Olsen B, Rits S
Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, βAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow.
Ann Integr Mol Med. 2020;2(1):90-114. PubMed: 32617536PAPER DeMarco ML, Nguyen Q, Fok A, Hsiung GR, van der Gugten JG
An automated clinical mass spectrometric method for identification and quantification of variant and wild-type amyloid-β 1-40 and 1-42 peptides in CSF.
Alzheimers Dement (Amst). 2020;12(1):e12036. Epub 2020 Jun 30 PubMed: 32617385PAPER Wickstead ES, Karim HA, Manuel RE, Biggs CS, Getting SJ, McArthur S
Reversal of β-Amyloid-Induced Microglial Toxicity In Vitro by Activation of Fpr2/3.
Oxid Med Cell Longev. 2020;2020:2139192. Epub 2020 Jun 13 PubMed: 32617132PAPER Kim GW, Kim BC, Park KS, Jeong GW
A pilot study of brain morphometry following donepezil treatment in mild cognitive impairment: volume changes of cortical/subcortical regions and hippocampal subfields.
Sci Rep. 2020 Jul 2;10(1):10912. PubMed: 32616841PAPER Chiotis K, Savitcheva I, Poulakis K, Saint-Aubert L, Wall A, Antoni G, Nordberg A
[18F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer's disease.
Mol Psychiatry. 2020 Jul 3; PubMed: 32616831PAPER Politis AM, Alexopoulos P, Vorvolakos T
May neuropsychiatric symptoms be a potential intervention target to delay functional impairment in Alzheimer's disease?
Int Psychogeriatr. 2020 Jun;32(6):689-691. PubMed: 32616115PAPER Topart C, Werner E, Arimondo PB
Wandering along the epigenetic timeline.
Clin Epigenetics. 2020 Jul 2;12(1):97. PubMed: 32616071PAPER Thomas KR, Osuna JR, Weigand AJ, Edmonds EC, Clark AL, Holmqvist S, Cota IH, Wierenga CE, Bondi MW, Bangen KJ, Alzheimer’s Disease Neuroimaging Initiative
Regional hyperperfusion in older adults with objectively-defined subtle cognitive decline.
J Cereb Blood Flow Metab. 2020 Jul 2;:271678X20935171. PubMed: 32615887PAPER Jack CR Jr
The transformative potential of plasma phosphorylated tau.
Lancet Neurol. 2020 May;19(5):373-374. PubMed: 32333888Current Filters
- Date Range : Jun 2020 to Jul 2020 x